Check out the past-year performance of TERN. This is the kind of move that can happen when big pharma sees an opportunity to acquire a company with sound technologies and was significantly undervalued at the time. I bought TERN around $2, the stock moved to around $8 when positive Phase 3 results were announced, and recently Merck & Co. announced a buyout at $53.
As soon as NWBO’s technologies get verified and validated by regulators, a major portion of the risk disappears. The unmet market opportunity is substantial, with potential much more future market ahead. For a treatment approach that appears to offer strong efficacy with minimal side effects, any rational company or investor (with half of a brain) would want to use it, partner with it, or potentially acquire it.
No one wants to against the trend includes shorts.
Market Data 
Markets 
AI
